Dr. Reddy’s halts semaglutide supplies on quality concerns, shares plunge, Torrent recalls product
Dr. Reddy’s Laboratories has halted commercial supplies of its generic semaglutide due to quality concerns regarding an active pharmaceutical ingredient. The announcement caused the company's shares to drop, and Torrent Pharmaceuticals has initiated a voluntary recall of affected batches.
Why it matters
The disruption affects the availability of critical diabetes and weight-loss medication, highlighting supply chain and quality control risks in the pharmaceutical industry.
Dr. Reddy’s Laboratories on Thursday said it has halted commercial supplies of its generic semaglutide after an issue associated with the active pharmaceutical ingredient (API) used in the drug and fresh despatches were likely to resume only towards late October or early November.
The article provides a factual report on corporate actions, market impact, and regulatory compliance without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in